Nucana Plc shares fall 5% premarket after recent presentation on clinical-stage biopharmaceutical developments.

Nucana Plc dropped 5% in premarket trading. The company is a United Kingdom-based clinical-stage biopharmaceutical company focused on developing treatment outcomes for patients with cancer by applying its ProTide technology. The company's pipeline includes NUC-3373, and NUC-7738. NUC-3373 is a ProTide transformation of the active anti-cancer metabolite of 5-fluorouracil (5-FU). 5-FU is a prescribed anti-cancer agent. NUC-3373 has been evaluated in a Phase I clinical trial for patients with advanced solid tumors and is under Phase Ib/II clinical trial for patients with advanced colorectal cancer. NUC-7738 is a ProTide transformation of a nucleoside analog, 3’-deoxyadenosine (3’-Da). The company is evaluating NUC-7738 in a Phase.